| IRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call Transcript |
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-05 18:52:02 |
Czytaj oryginał (ang.) |
| IRadimed (IRMD) Lags Q1 Earnings Estimates |
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago. |
zacks.com |
2025-05-05 13:11:04 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION Announces First Quarter 2025 Financial Results |
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024. Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024. |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025 |
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025". The corrected release follows: |
globenewswire.com |
2025-04-28 13:53:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025 |
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. |
globenewswire.com |
2025-04-28 12:30:00 |
Czytaj oryginał (ang.) |
| IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space |
IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possibly due to cheaper alternatives in Asian markets. |
seekingalpha.com |
2025-04-08 17:25:26 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference |
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference. |
globenewswire.com |
2025-03-10 10:30:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript |
IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-13 17:11:45 |
Czytaj oryginał (ang.) |
| IRadimed (IRMD) Lags Q4 Earnings Estimates |
IRadimed (IRMD) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago. |
zacks.com |
2025-02-13 12:46:17 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025 |
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. |
globenewswire.com |
2025-01-30 10:30:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues |
WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024. |
globenewswire.com |
2025-01-10 10:30:00 |
Czytaj oryginał (ang.) |
| iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why |
If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-12-30 11:50:31 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. |
globenewswire.com |
2024-12-19 10:30:00 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in iRadimed (IRMD) Should Keep going |
iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-12-13 11:51:13 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025 |
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. |
globenewswire.com |
2024-12-10 10:30:00 |
Czytaj oryginał (ang.) |
| iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable |
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-11-07 11:50:20 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024 |
WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. |
globenewswire.com |
2024-11-04 10:30:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript |
IRADIMED CORPORATION. (NASDAQ:IRMD ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Third Quarter of 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-10-31 21:52:17 |
Czytaj oryginał (ang.) |
| IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates |
IRadimed (IRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.43 per share a year ago. |
zacks.com |
2024-10-31 12:26:16 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share |
WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and a non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. |
globenewswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st |
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. |
globenewswire.com |
2024-10-24 20:05:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference |
WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference. |
globenewswire.com |
2024-10-03 20:05:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference |
WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8 th Annual Best Ideas Growth "Big 8" Conference. |
globenewswire.com |
2024-09-10 20:30:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript |
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2024 Results Conference Call August 1, 2024 12:00 PM ET Company Participants Roger Susi - President and Chief Executive Officer Matt Garner - Controller Conference Call Participants Frank Takkinen - Lake Street Capital Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Second Quarter of 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 1, 2024, and contains time-sensitive accurate information only today. |
seekingalpha.com |
2024-08-03 22:17:06 |
Czytaj oryginał (ang.) |
| IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates |
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.36 per share a year ago. |
zacks.com |
2024-08-01 14:50:30 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share |
WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. |
globenewswire.com |
2024-08-01 13:29:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st |
Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions. |
globenewswire.com |
2024-07-25 12:30:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market |
WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD. |
globenewswire.com |
2024-06-07 12:30:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript |
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2024 Results Conference Call May 2, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Frank Takkinen - Lake Street Capital Operator Welcome to IRADIMED CORPORATION First Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode, and at the end of the call, we will conduct a question-and-answer session. |
seekingalpha.com |
2024-05-04 17:27:07 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share |
WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. |
globenewswire.com |
2024-05-02 12:30:00 |
Czytaj oryginał (ang.) |
| IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd |
WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. |
globenewswire.com |
2024-04-25 20:05:00 |
Czytaj oryginał (ang.) |